Calendar

Week of Apr 20, 2026

Apr 24, 2026phase 1 initiation110d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

full page →CMSD-001 →source: globaldata

Apr 24, 2026phase 2 completion110d agoKothiwal Dental College and Research Centre — platelet rich plasma (Phase II Trial Completion)platelet rich plasma

Therapy area: Dermatology. Indication: Androgenic Alopecia

full page →platelet rich plasma →source: globaldata

Apr 24, 2026phase 2 completion110d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

full page →lixudebart →source: globaldata

Apr 24, 2026phase 2 initiation110d agoSRM Kattankulathur Dental College and Hospital — human placental extract (Phase II Trial Initiation)human placental extract

Therapy area: Dermatology. Indication: Wounds

full page →human placental extract →source: globaldata

Apr 24, 2026phase 3 completion110d agoBioClever 2005 SL — minoxidil (Phase III Trial Completion)minoxidil

Therapy area: Dermatology. Indication: Androgenic Alopecia

full page →minoxidil →source: globaldata

Apr 24, 2026phase iv trial initiation110d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

full page →melatonin →source: globaldata

Apr 24, 2026phase iv trial initiation110d agoDr Rajendra Prasad Centre for Ophthalmic Sciences — carboxymethylcellulose (Phase IV Trial Initiation)carboxymethylcellulose

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

full page →carboxymethylcellulose →source: globaldata

Apr 25, 2026phase 0 trial completion109d agoExegenesis Bio Inc — EXG-202 (Phase 0 Trial Completion)EXG-202

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Macular Degeneration, Wet (Neovascular / Exudative) Macular Degeneration

full page →EXG-202 →source: globaldata

Apr 25, 2026phase 1 completion109d agoBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)YTS-109

Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia

full page →YTS-109 →source: globaldata

Apr 25, 2026phase 2 completion109d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

full page →Himani fast relief gel →source: globaldata

Apr 25, 2026phase 2 initiation109d agoKIMS Hospital — bifidobacterium (Phase II Trial Initiation)bifidobacterium

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →bifidobacterium →source: globaldata

Apr 25, 2026phase 2 initiation109d agoGlenmark Pharmaceuticals Ltd — (clascoterone + latanoprost) (Phase II Trial Initiation)(clascoterone + latanoprost)

Therapy area: Dermatology. Indication: Androgenic Alopecia

full page →(clascoterone + latanoprost) →source: globaldata

Apr 25, 2026phase 3 initiation109d agoDr. Reddy's Laboratories Ltd — olokizumab (Phase III Trial Initiation)olokizumab

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →olokizumab →source: globaldata

Week of Apr 20, 2026